+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Alpha Synuclein"

Alpha-Synuclein (alphaSyn Or SNCA) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Alpha-Synuclein (alphaSyn Or SNCA) Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
From
Lewy Body Dementia Global Market Report 2025 - Product Thumbnail Image

Lewy Body Dementia Global Market Report 2025

  • Report
  • January 2025
  • 175 Pages
  • Global
From
Parkinson's Disease Drugs - Global Strategic Business Report - Product Thumbnail Image

Parkinson's Disease Drugs - Global Strategic Business Report

  • Report
  • July 2025
  • 382 Pages
  • Global
From
Neurodegenerative Drugs - Global Strategic Business Report - Product Thumbnail Image

Neurodegenerative Drugs - Global Strategic Business Report

  • Report
  • July 2025
  • 376 Pages
  • Global
From
From
Parkinson's Disease Market Report and Forecast 2025-2034 - Product Thumbnail Image

Parkinson's Disease Market Report and Forecast 2025-2034

  • Report
  • June 2025
  • 400 Pages
  • Global
From
From
From
From
From
From
  • 18 Results (Page 1 of 1)
Loading Indicator

Alpha Synuclein is a protein found in the brain and other parts of the nervous system. It is involved in the regulation of neurotransmitter release and is believed to play a role in the development of Parkinson's disease. As such, it has become an important target for drug development in the Central Nervous System (CNS) drugs market. Alpha Synuclein-targeting drugs are being developed to treat Parkinson's disease, as well as other neurological disorders such as dementia and multiple system atrophy. These drugs are designed to reduce the amount of Alpha Synuclein in the brain, which is believed to be a major contributor to the progression of these diseases. In addition to drug development, research is also being conducted into the role of Alpha Synuclein in other neurological disorders, such as Alzheimer's disease and amyotrophic lateral sclerosis. This research is aimed at understanding the role of Alpha Synuclein in the development of these diseases, and developing treatments that target the protein. Companies in the Alpha Synuclein market include AbbVie, Biogen, Merck, Novartis, and Pfizer. Show Less Read more